A Phase 1/2 interventional study of Mosunetuzumab Intravenous (IV) and Mosunetuzumab Subcutaneous (SC) in Diffuse Large B-cell Lymphoma, sponsored by Hoffmann-La Roche. Completed at 32 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-21.
Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing polatuzumab vedotin in Lymphoma, Large B-Cell, Diffuse — 15 open to participants now, 18 under way, 1 of them phase 3. polatuzumab vedotin · Lymphoma, Large B-Cell, Diffuse.
Among the 28 studies testing polatuzumab vedotin in Lymphoma, Large B-Cell, Diffuse, this one is the 6th largest by enrollment, is the only one that started in 2019, is one of 4 in phase 1/2, and was the 3rd registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →15 of the 28 studies testing polatuzumab vedotin in Lymphoma, Large B-Cell, Diffuse are open now, in 2 countries. Recruiting first, the newest first:
The First Hospital of Jilin University · Sites in China
Ages 65+
Medical College of Wisconsin · Sites in United States
Ages 70+
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 60+
Shanghai Zhongshan Hospital · Sites in China
Ages 70+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75
By country, each count listing its studies:
polatuzumab vedotin: first FDA approval 2019 (POLIVY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 20 · Phase 3 5 · Phase 4 1
First in 2016; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 188 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 42 across the 28 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 28 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
28 studies in Lymphoma, Large B-Cell, Diffuse by Hoffmann-La Roche: 2 open now, 5 under way, 1 of them phase 3. Of 22 finished, 13 (59%) have results posted.
Among the 28 studies in Lymphoma, Large B-Cell, Diffuse by Hoffmann-La Roche, this one is the 8th largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2019, is one of 5 in phase 1/2, and was the 18th registered.
Hoffmann-La Roche’s Lymphoma, Large B-Cell, Diffuse studies by the year they started, since 2005.
2 of the studies testing polatuzumab vedotin in Lymphoma, Large B-Cell, Diffuse that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07012980Shanghai Zhongshan HospitalGlofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL | 2027-03-31 |
| NCT06015880National Cancer Institute (NCI)Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies testing polatuzumab vedotin in Lymphoma, Large B-Cell, Diffuse, from their registry updates:
Among Hoffmann-La Roche’s 28 in Lymphoma, Large B-Cell, Diffuse:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab following first-line diffuse large B-cell lymphoma (DLBCL) immunochemotherapy in participants with a best response of stable disease or partial response, or in elderly/unfit participants with previously untreated DLBCL, or subcutaneous mosunetuzumab in combination with polatuzumab vedotin IV in elderly/unfit participants with previously untreated DLBCL.
Inclusion Criteria for All Cohorts
Inclusion Criteria Specific to Cohort A
Participants in Cohort A must also meet the following criteria for study entry:
Inclusion Criteria Specific to Cohorts B and C
Participants in Cohorts B and C must also meet the following criteria for study entry:
Exclusion Criteria for All Cohorts
Participants who meet any of the following criteria will be excluded from study entry:
Exclusion Criteria Specific to Cohort A
Participants in Cohort A who meet the following criteria will be excluded from study entry:
- Prior anti-lymphoma treatment with chemotherapy, immunotherapy, or biologic therapy 4 weeks prior to C1D1
Exclusion Criterion Specific to Cohorts B and C
Participants in Cohorts B and C who meet the following criterion will be excluded from study entry:
- Prior treatment for DLBCL with chemotherapy, immunotherapy, and biologic therapy
Exclusion Criteria Specific to Cohort C
Participants in Cohort C who meet the following criteria will be excluded from study entry:
- Current Grade >1 peripheral neuropathy by clinical examination or demyelinating form of Charcot-Marie-Tooth disease
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with a partial response to first-line chemotherapy will receive mosunetuzumab up to the recommended consolidation dose (RCD).
Drug: Mosunetuzumab Intravenous (IV) · Drug: Tocilizumab
Elderly/unfit participants with previously untreated DLBCL will receive mosunetuzumab at the previously determined recommended phase II dose (RP2D).
Drug: Mosunetuzumab Intravenous (IV) · Drug: Tocilizumab
Elderly/unfit participants with previously untreated DLBCL will receive mosunetuzumab in combination with polatuzumab vedotin.
Drug: Mosunetuzumab Subcutaneous (SC) · Drug: Polatuzumab Vedotin · Drug: Tocilizumab
Participants in cohorts A and B will receive IV mosunetuzumab.
Participants in Cohort C will receive SC mosunetuzumab.
Participants in Cohort C will receive IV polatuzumab vedotin.
Participants will receive tocilizumab via IV as needed to manage severe cytokine release syndrome (CRS).
Percentage of Participants with Adverse Events
Time frame: Baseline through approximately 90 days after last study treatment
Positron Emission Tomography-Computed Tomography (PET-CT) Complete Response (CR) Rate at Time of Primary Response Assessment (PRA) According to Lugano 2014 Response Criteria (Cohort A)
Time frame: 6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days)
PET-CT Objective Response Rate (ORR) at PRA According to Lugano 2014 Response Criteria as Determined by the Investigator (Cohort B)
Time frame: 6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days)
PET-CT ORR at PRA According to the Lugano 2014 Criteria as Determined by an Independent Review Committee (IRC) (Cohort C)
Time frame: 6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days)
Maximum Serum Concentration (Cmax) of Mosunetuzumab IV
Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
Minimum Serum Concentration (Cmin) of Mosunetuzumab IV
Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
Area Under the Curve (AUC) of Mosunetuzumab IV
Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
Clearance (CL) of Mosunetuzumab IV
Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
Volume of Distribution at Steady State (Vss) of Mosunetuzumab IV
Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
Maximum Serum Concentration (Cmax) of Mosunetuzumab SC
Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
Time to Maximum Serum Concentration (Tmax) of Mosunetuzumab SC
Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
Minimum Serum Concentration (Cmin) of Mosunetuzumab SC
Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
Area Under the Curve (AUC) of Mosunetuzumab SC
Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
Clearance (CL) of Mosunetuzumab SC
Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
Volume of Distribution at Steady State (Vss) of Mosunetuzumab SC
Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
Maximum Serum Concentration (Cmax) of Polatuzumab Vedotin IV
Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
Minimum Serum Concentration (Cmin) of Polatuzumab Vedotin IV
Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
Area Under the Curve (AUC) of Polatuzumab Vedotin IV
Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
Clearance (CL) of Polatuzumab Vedotin IV
Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
Volume of Distribution at Steady State (Vss) of Polatuzumab Vedotin IV
Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
End of Infusion Concentration (Ceoi) of Polatuzumab Vedotin IV
Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
Trough Concentration (Ctrough) of Polatuzumab Vedotin IV
Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
PET-CT Rate According to the Lugano 2014 Criteria at PRA as Determined by the Investigator (Cohorts B and C) and IRC (Cohort C)
Time frame: 6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days)
Objective Response Rate (ORR), Defined as the Proportion of Participants with a Complete Response (CR) or Partial Response (PR) at PRA as Determined by the Investigator (Cohorts A and C)
Time frame: Baseline through 2 years after PRA (up to a total of approximately 2.5 years)
Best ORR (CR or PR at any time) During the Study Based on PET-CT and/or CT Scans as Determined by the Investigator (All Cohorts) and by IRC (Cohort C)
Time frame: Baseline through 2 years after PRA (up to a total of approximately 2.5 years)
Duration of Response (DOR) as Determined by the Investigator (All Cohorts) and by IRC (Cohort C)
Time frame: From the first occurrence of a documented objective response to disease progression, relapse, or death, whichever occurs first (up to approximately 2.5 years)
Duration of Confirmed Response (DOCR) as Determined by the Investigator (All Cohorts) and by IRC (Cohort C)
Time frame: From the first occurrence of a documented CR to disease progression or relapse, or death from any cause, whichever occurs first (up to approximately 2.5 years)
Progression-Free Survival (PFS) as Determined by the Investigator (All Cohorts) and by IRC (Cohort C)
Time frame: From the first study treatment to the first occurrence of disease progression, relapse, or death, whichever occurs first (up to approximately 2.5 years)
Overall Survival (OS)
Time frame: From the first study treatment to death from any cause
Time to Deterioration in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Physical Functioning and Fatigue (Cohorts B and C)
Time frame: From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)
Time to Deterioration in European Organization for Research and Treatment of Cancer Item Library (EORTC-IL17) Physical Functioning (Cohorts B and C)
Time frame: From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)
Time to Deterioration in the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale (Cohorts B and C)
Time frame: From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)
Proportion of Participants Achieving a Clinically Meaningful Improvement in Physical Functioning as Measured by EORTC QLQ-C30 (Cohorts B and C)
Time frame: From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)
Proportion of Participants Achieving a Clinically Meaningful Improvement in Physical Functioning as Measured by EORTC IL17 (Cohorts B and C)
Time frame: From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)
Anti-Drug Antibodies (ADAs) to Mosunetuzumab
Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
Anti-Drug Antibodies (ADAs) to Polatuzumab Vedotin (Cohort C)
Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
No publications or documents are linked to this record.
Ran from May 2019 to primary completion in Aug 2025, 74 months.
Of 51 industry-sponsored phase 1/2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 99. This study's 74 months is close to that.
Counting every sponsor, half of 108 studies reached it within 70 months; a quarter within 50 and three quarters within 98.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Mosunetuzumab · Polatuzumab vedotin
Lymphoma, Large B-Cell, Diffuse →